Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Michelle H. Braccioforte"'
Autor:
Manuj Agarwal, Antony Koroulakis, C. DeCesaris, Michelle H. Braccioforte, Brian J. Moran, Neha P. Amin
Publikováno v:
Brachytherapy. 20:38-43
Purpose Iodine-125 (125I) is the most commonly used isotope for prostate brachytherapy (BT). Cesium-131 (131Cs) has a higher dose rate and shorter dose delivery time resulting in decreased duration of acute urinary morbidity. Long-term data suggest e
Autor:
Neha P. Amin, Stephanie R. Rice, Arpit M. Chhabra, Manuj Agarwal, Brian J. Moran, Michelle H. Braccioforte
Publikováno v:
Brachytherapy. 18:800-805
Purpose Long-term outcomes reveal equivalent biochemical outcomes with low-dose-rate (LDR) brachytherapy (BT) compared with radical prostatectomy and external-beam radiotherapy for the management of prostate cancer. Iodine-125, the most commonly used
Autor:
Eyad Abu-Isa, Albert J. Chang, Wolfgang Lilleby, Jeffrey J. Tosoian, Robert E. Reiter, Brian J. Moran, Robert T. Dess, Trude B. Wedde, Theodore L. DeWeese, D. Jeffrey Demanes, Patrick A. Kupelian, Todd McNutt, Ridwan Alam, Prashant Bhat, Tahmineh Romero, Santiago Martin, Daniel E. Spratt, Thomas M. Pisansky, Nicholas G. Nickols, Giovanni Motterle, Rafael Martínez-Monge, J.K. Wong, Gregory S. Merrick, Derya Tilki, Matthew Rettig, R. Jeffrey Karnes, Jesus E. Juarez, Michael L. Steinberg, Phuoc T. Tran, Hartwig Huland, Bradley J. Stish, Eric M. Horwitz, David Elashoff, Danny Y. Song, Bruce J. Trock, Alejandro Berlin, Chandana A. Reddy, David Shabsovich, Daniel J. Krauss, Brian J. Davis, Eric A. Klein, Michelle H. Braccioforte, Curtiland Deville, Rahul D. Tendulkar, Richard G. Stock, Natalie Chong, Paul C. Boutros, Jay P. Ciezki, Jonathan D. Tward, Ryan Fiano, Rebecca Levin-Epstein, Zeyad Schwen, Richard Choo, Ashley E. Ross, Avinash Pilar, Anthony V. D'Amico, Amar U. Kishan, Stephen Greco
Publikováno v:
JAMA Network Open
Key Points Question Are external beam radiotherapy, with or without brachytherapy boost, or radical prostatectomy associated with differences in prostate cancer–specific mortality or distant metastasis outcomes in patients with high-risk prostate c
Autor:
Ming-Hui Chen, Brian J. Moran, Michelle H. Braccioforte, Jing Wu, Anthony V. D'Amico, David D. Yang
Publikováno v:
Urologic oncology. 40(1)
We evaluated whether intermediate-risk factors, in addition to age, were associated with risk of prostate cancer-specific mortality (PCSM) among men with Gleason 3+4 prostate cancer.We conducted a prospective cohort study of 1,920 men with Gleason 3+
Autor:
Jason K. Molitoris, Arpit M. Chhabra, Manuj Agarwal, Michelle H. Braccioforte, Neha P. Amin, Brian J. Moran
Publikováno v:
Brachytherapy. 17:882-887
Purpose The available data demonstrating that superiority of LDR brachytherapy (LDR-BT) boost in high-risk prostate cancer patients under represents patients with extracapsular extension (T3a) and/or seminal vesicle invasion (T3b) have been limited.
Publikováno v:
Brachytherapy. 20:S74-S75
Autor:
Richard G. Stock, Trude B. Wedde, Rebecca Levin-Epstein, Michael L. Steinberg, Matt Rettig, Phuoc T. Tran, R. Jeffrey Karnes, Andrew J. Stephenson, Christopher R. King, Amar U. Kishan, Eric M. Horwitz, Tahmineh Romero, Derya Tilki, David Elashoff, Ryan Fiano, Nicholas G. Nickols, Gregory S. Merrick, Robert E. Reiter, Daniel E. Spratt, Brian J. Moran, Eric A. Klein, Wolfgang Lilleby, Rahul D. Tendulkar, Robert T. Dess, D. Jeffrey Demanes, Jonathan D. Tward, Daniel J. Krauss, Michelle H. Braccioforte, Chandana A. Reddy, J. Karen Wong, Giovanni Motterle, Bradley J. Stish, Brian J. Davis
Publikováno v:
Journal of Urology. 203
INTRODUCTION AND OBJECTIVE:External beam radiotherapy (EBRT) with androgen deprivation therapy (ADT), EBRT with a brachytherapy boost (EBRT+BT) with ADT, and radical prostatectomy (RP) with or with...
Autor:
Brian J, Moran, Antony, Koroulakis, Cristina, Decesaris, Michelle H, Braccioforte, Neha, Amin, Manuj, Agarwal
Publikováno v:
Brachytherapy. 20(1)
Iodine-125 (Patients with low- or intermediate-risk disease were treated with a BT in a single outpatient facility. Prescription dose was 144 Gy forOne hundred forty men were enrolled; 81.4% were low-risk and 18.6% were intermediate-risk. The median
Autor:
Stephen A. Mihalcik, Brian J. Moran, Anthony V. D'Amico, Ming-Hui Chen, Michelle H. Braccioforte
Publikováno v:
European Urology Focus. 4:64-67
17 Background: On July 19, 2012, the Prostate Cancer Intervention versus Observation Trial (PIVOT) was published and reported that after a median follow up of 10 years, radical prostatectomy neither improved overall survival nor reduced prostate canc
Autor:
Michelle H. Braccioforte, Sharon Salenius, Anthony V. D'Amico, Ming-Hui Chen, R. Ross, Brian J. Moran, Daniel E. Doseretz, Michael J. Katin, Jing Wu, Brent S. Rose
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 96:778-784
Purpose The addition of androgen deprivation therapy (ADT) to radiation therapy (RT) is the standard of care for men with intermediate- and high-risk prostate cancer (PC). However, whether competing mortality (CM) affects the ability of ADT to improv